- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00187798
Impact of Genetics on Metformin Pharmacokinetics
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Twin studies have long been a valuable tool for examining the relative role of environment and heredity in health issues such as disease and drug response. For example, twin studies in the 1960's and 1970's showed for the first time that variability in the elimination of many drugs was largely influenced by heredity. Monozygotic twin pairs showed little variability in the elimination of various drugs while dizygotic twin pairs, sharing only about one half of their genes, showed much greater variability. It is now known that the some of the variability in drug elimination observed in dizygotic twins was due to genetic differences in drug metabolizing enzymes, such as the cytochrome P450's. However, genetic variation in other genes, such as membrane transporters may also contribute to variability in drug response.
Membrane transporters play multiple roles in the body; they help to maintain cellular homeostasis through import and export mechanisms and also play an important role in drug response, affecting both the pharmacokinetics and pharmacodynamics of drugs. Animal studies using mice genetically deficient in drug transporters and reports of drug interaction studies involving transporter substrates have provided convincing evidence that the level of function of several important drug transporters is an important determinant of drug response.
The current study will examine differences in the renal clearance of metformin in monozygotic and dizygotic twin pairs. Metformin is an antidiabetic drug that has no significant hepatic metabolism and is actively secreted by the kidneys. Studies in our lab have shown that metformin is a substrate of the human organic cation transporter, hOCT2, which appears to be a major transporter involved in the renal secretion of cationic drugs. Data in the literature indicate that there is substantial variation in the net secretory clearance of metformin in normal, healthy volunteers. In five healthy volunteers, the ratio of renal clearance to creatinine clearance ranged from 1.5 to 4.2, nearly a 3-fold variation. We hypothesize that genetic variation in secretory transporters in the kidney, like hOCT2, may be responsible for the inter-individual differences in the secretory clearance of metformin and other drugs. Studies examining renal clearance of metformin in monozygotic and dizygotic twins will allow us to better understand the influence of heredity on variation in renal elimination. Furthermore, genotyping monozygotic and dizygotic twin pairs with significant differences in renal clearance of metformin may give us insight into the genes responsible for this variability.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
California
-
San Francisco, California, Forenede Stater, 94143
- University of California San Francsico
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Part of either a monozygotic or dizygotic twin pair.
- Healthy (by medical history and laboratory values).
- Between 18 and 40 years old.
Exclusion Criteria:
- Taking regular medication other than vitamins.
- Individuals with anemia (hemoglobin < 12 g/dL), an elevation in liver enzymes to higher than double the respective normal value, or elevated creatinine concentrations (males ≥ 1.5 mg/dL, females ≥ 1.4 mg/dL Pregnant at time of study.
- Diagnosis of hypoglycemia, phlebitis and/or stroke will be excluded.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Andet: Metformin
Metformin HCl
|
Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
To compare metformin pharmacokinetics in monozygotic and dizygotic twin pairs.
Tidsramme: 24 hours
|
Comparing renal clearance of metformin in monozygotic and dizygotic twins will allow us to better understand the influence of heredity on variation in renal elimination.
Furthermore, genotyping renal transporter genes in monozygotic and dizygotic twin pairs with significant differences in renal clearance of metformin may give us insight into the genes responsible for this variability.
|
24 hours
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Kathleen Giacomini, PhD, University of California San Francsico
Publikationer og nyttige links
Generelle publikationer
- Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics. 2003 Sep;13(9):581-4. doi: 10.1097/00008571-200309000-00007.
- Leabman MK, Huang CC, Stryke D, Johns SJ, Kawamoto M, Ferrin TE, DeYoung J, Taylor TR, De La Cruz M, Herskowitz I, Giacomini KM. PharmGKB update: I. Genetic variants of the organic cation transporter 2 (OCT2, SLC22A2). Pharmacol Rev. 2003 Sep;55(3):399. doi: 10.1124/pr.55.3.6. Epub 2003 Jul 17. No abstract available.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 928
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Metformin HCl
-
Daiichi Sankyo, Inc.AfsluttetType 2 diabetes mellitusForenede Stater
-
Bristol-Myers SquibbAfsluttetDiabetes mellitus, ikke-insulinafhængigForenede Stater
-
LG Life SciencesAfsluttet
-
LG Life SciencesAfsluttet
-
LG Life SciencesAfsluttet
-
Boston Children's HospitalAfsluttet
-
Amsterdam UMCZonMw: The Netherlands Organisation for Health Research and DevelopmentIkke rekrutterer endnuPræeklampsi | HELLP syndrom | Præeklampsi eller eklampsi med allerede eksisterende hypertension | HJÆLP | Præeklampsi; Komplicerer graviditet | Præeklampsi debut mindre end 37 uger | Præeklampsi som førfødselstilstand | Præeklampsi; Påvirker fosteret | HELLP syndrom komplicerer graviditet
-
Children's Hospital Los AngelesAfsluttetHyperglykæmi | Diabetes mellitus | Insulin resistens | Akut lymfatisk leukæmiForenede Stater
-
Torrent Pharmaceuticals LimitedAfsluttet
-
Torrent Pharmaceuticals LimitedAfsluttet